Skip to Main Content

Paper Details

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Oncologist
20
2022
DLL3, NEC, NEN, NENs, NET, Neuroendocrine, Neuroendocrine Neoplasms, Neuroendocrine neoplasms, Notch receptor, SCLC, Ts, delta-like ligand 3, malignancies, neuroendocrine carcinomas, neuroendocrine tumors, patients, small-cell lung cancer, tumor, well-differentiated
Author NameAffiliation
Rahul AggarwalUCSF Helen Diller Family Comprehensive Cancer Center
Himisha BeltranDana-Farber Cancer Institute
Himisha BeltranDana-Farber Cancer Institute
  • 1 - 3

Datasets

Release 1.2